Everolimus plus reduced calcineurin inhibitor prevents <em>de novo</em> anti-HLA antibodies and humoral rejection in kidney transplant recipients: 12-month results from the ATHENA study
CONCLUSION: The EVR regimen was comparable to MPA regimen with an extremely low incidence of dnDSA over 1 year of …